Semaglutide long-term safety: what the clinical evidence actually shows

A year in, and you're wondering what continued use means for your body

Picture someone twelve months into weekly semaglutide injections. The nausea that troubled the first few weeks has largely gone. Weight is down. But the question that arrives quietly (often around the time a repeat prescription is due) is: what does staying on this for two, three, or more years actually do?

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and remains one of the largest long-term semaglutide datasets for weight management. Participants on 2.4mg semaglutide achieved an average body-weight reduction of around 15%, and the trial recorded safety events systematically throughout. The gastrointestinal side-effect pattern that emerged (nausea, diarrhoea, constipation, vomiting) was most prominent in the early months and generally settled without stopping treatment. Serious adverse events were not significantly more frequent in the semaglutide group than placebo at the population level, though individuals varied considerably.

Real-world use since then, across millions of patients, has broadly reflected that picture. The NHS medicines page for semaglutide lists the known side effects clearly, distinguishing common from rare, and notes that most GI effects are transient. That doesn't mean everyone sails through (some people do stop treatment because of persistent symptoms) but it does mean this isn't an uncharted landscape.

The risks that need watching over time, not just at the start

A question our prescribers hear most weeks is some version of: "I felt fine for months, then developed this — could the medication still be responsible?" The honest answer is: sometimes yes, which is why ongoing clinical monitoring matters more than a one-off assessment at the start.

Gallbladder disease is a recognised long-term risk. Rapid weight loss of any cause increases gallstone formation risk, and semaglutide-associated weight loss is no exception. Symptoms (right-sided upper abdominal pain, particularly after eating fatty food) should prompt medical review rather than watchful waiting.

Acute pancreatitis is infrequent but serious. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging pancreatitis: severe, persistent stomach pain that may spread to the back, with or without vomiting, warrants urgent medical attention. Stop the injection and seek same-day assessment; do not wait for your next prescriber review.

Kidney function can be affected indirectly. Severe vomiting or diarrhoea leads to dehydration, which stresses the kidneys. People who are unwell with significant GI symptoms should stay well hydrated and seek advice if they can't keep fluids down. For a fuller breakdown of how individual side effects evolve over time, the long-term side effects of semaglutide page goes into each one in detail.

When to get medical help, and what doesn't need an emergency call

Getting this calibration right matters. Most people on semaglutide experience some nausea; that alone rarely needs urgent attention, though it's always worth mentioning at your next review. A few things are different.

Seek same-day medical help if you develop: severe abdominal pain (especially radiating to the back), signs of an allergic reaction such as swelling of the face or throat, sudden worsening of eyesight, or signs of serious dehydration, dizziness, very dark urine, or inability to drink. These are not exhaustive, and the Patient Information Leaflet supplied with your pen is the definitive reference.

Mood changes are worth raising with your prescriber, not ignoring. Reports of low mood and, in rare cases, thoughts of self-harm have been noted in post-marketing surveillance for GLP-1 medicines. The causal relationship remains under investigation, but the MHRA takes these reports seriously, and so do we. Our Wegovy safety overview covers the psychological monitoring picture in more depth, and if you want a closer look at how Wegovy side effects present and progress across the full treatment period, that page walks through what patients commonly report at each stage.

For anything that doesn't feel urgent but is still bothering you between prescriber check-ins, the contact page connects you to our aftercare team, seven days a week.

What the evidence doesn't yet tell us, and why that's an honest answer, not a red flag

Semaglutide for weight management has been widely available since 2021. That's meaningful follow-up time for a medicine, but it isn't decades. For most people, the benefit-to-risk calculation at population level looks favourable, the SELECT trial, which ran for over three years in adults with cardiovascular disease, showed semaglutide reduced major cardiac events, suggesting long-term cardiovascular safety is not a concern for most patients and may actively confer benefit. The question of how safe Wegovy is over the long term is one clinicians and regulators continue to monitor actively, which is the right approach for any relatively new medicine carrying Black Triangle (▼) status.

Areas where evidence is still accumulating include: the appropriate duration of treatment before a planned break, long-term thyroid and endocrine effects in humans (signals in rodent studies haven't translated to human data so far, but monitoring continues), and the optimal approach for people with a personal or family history of specific thyroid tumours. None of this should stop an appropriate patient from using the medicine; it should inform the conversation with a prescriber.

The semaglutide safety evidence by duration page examines the trial data year by year for readers who want that level of granularity, and for a broader picture of how semaglutide safety is assessed and monitored across different patient groups, that dedicated overview brings together the current guidance in one place. If you're at the stage of deciding whether to start, our prescribers discuss safety and suitability as part of every free consultation, you'll have the chance to ask these questions before any prescription is issued. Start your free consultation to speak with a GPhC-registered prescriber directly.